iLof Secures $5m

ILof Secures $5m to Expand its Digital Library of Biomarkers Aimed at Tackling the World’s Deadliest Diseases

Digital health company iLoF is pioneering a breakthrough  AI-platform to accelerate the future of personalized drug discovery and development.

This new funding round attracted world-class venture capital funds including M12, Microsoft’s Venture Fund, Faber Ventures, Lunar Ventures, and renowned global angel investors.

Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. 

Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, and has been regularly featured by outlets like Tech Crunch, Wired, or Sifted as a rising star in AI-Driven Drug Discovery, Health Screening & Data Analytics

iLof company was funded on the first round of Inno4cov-19 Project Open Call